PASSAGE BIO INC (PASG) Stock Price, Quote, News and Overview
NASDAQ:PASG - Nasdaq - US7027121000 - Common Stock - Currency: USD
PASG Quote, Performance and Key Statistics
PASSAGE BIO INC
NASDAQ:PASG (2/5/2025, 8:19:29 PM)
After market: 0.5901 -0.01 (-1.5%)0.5991
-0.01 (-1.79%)
The current stock price of PASG is 0.5991 USD. In the past month the price decreased by -21.58%. In the past year, price decreased by -39.94%.
PASG Latest News, Press Releases and Analysis
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data...
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PASG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About PASG
Company Profile
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 58 full-time employees. The company went IPO on 2020-02-28. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Company Info
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: Bruce Goldsmith
Employees: 58
Company Website: https://www.passagebio.com/
Investor Relations: https://investors.passagebio.com/
Phone: 12678660312
PASG FAQ
What is the stock price of PASG?
The current stock price of PASG is 0.5991 USD.
What is the symbol for PASSAGE BIO INC stock?
The exchange symbol of PASSAGE BIO INC is PASG and it is listed on the Nasdaq exchange.
On which exchange is PASG stock listed?
PASG stock is listed on the Nasdaq exchange.
Is PASG a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PASG, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PASG.
Does PASG stock pay dividends?
PASG does not pay a dividend.
When does PASG stock report earnings?
PASG will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of PASG?
PASG does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
What is the Short Interest ratio of PASG stock?
The outstanding short interest for PASG is 3.33% of its float.
PASG Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PASG. When comparing the yearly performance of all stocks, PASG is a bad performer in the overall market: 87.02% of all stocks are doing better.
PASG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PASG. PASG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PASG Financial Highlights
Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by 42.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.56% | ||
| ROE | -94.61% | ||
| Debt/Equity | 0 |
PASG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to PASG. The Buy consensus is the average rating of analysts ratings from 11 analysts.